Advances in the management of pancreatic cystic neoplasms

Walsh, R. Matthew; Perlmutter, Breanna; Adsay, Volkan; Reid, Michelle D.; Baker, Mark E.; Stevens, Tyler; Hue, Jonathan J.; Hardacre, Jeffrey M.; Shen, Gong-Qing; Šimon, Róbert; Aleassa, Essa M.; Augustin, Toms; Eckhoff, Austin; Allen, Peter J.; Goh, Brian K. P.

doi:10.1016/j.cpsurg.2020.100879

Cited by 8 publications

(17 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it is one of the most lethal solid tumours despite the use of a multi-approach strategy. The remaining 15% consists of numerous diverse neoplasms, both malignant and benign [ 1 , 2 ]. It is important to mention that some rare pancreatic tumours, such as mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN), can transform into PDAC [ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…The remaining 15% consists of numerous diverse neoplasms, both malignant and benign [ 1 , 2 ]. It is important to mention that some rare pancreatic tumours, such as mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN), can transform into PDAC [ 1 , 2 ]. Due to the heterogeneity of these rare tumours, accurate diagnosis is crucial for choosing the appropriate treatment, as management varies in different types.…”

Section: Introductionmentioning

confidence: 99%

“…For example, up to 15% of pancreatic cystic lesions (PCLs) are detected by MRIs performed for unrelated reasons [ 3 ]. However, more precise methods for diagnosis and malignancy markers still need to be developed to correctly identify lesions, implement appropriate treatment and avoid unnecessary surgery [ 2 ]. A low incidence rate of lesions other than PDAC in the pancreas results in fewer articles and less data; hence, in this review, we compiled the latest information about selected rare, non-neuroendocrine pancreatic tumours involving their clinical features, differential diagnoses, prognoses and treatments.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rare Non-Neuroendocrine Pancreatic Tumours

Mormul

Włoszek

Nowoszewska

et al. 2023

Cancers

View full text Add to dashboard Cite

The most common tumour of the pancreas is ductal adenocarcinoma (PDAC). It remains one of the most lethal non-neuroendocrine solid tumours despite the use of a multi-approach strategy. Other, less-common neoplasms, which are responsible for 15% of pancreatic lesions, differ in treatment and prognosis. Due to the low incidence rate, there is a lack of information about the rarest pancreatic tumours. In this review, we described six rare pancreatic tumours: intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma (MCN), serous cystic neoplasm (SCN), acinar cell carcinoma (ACC), solid pseudopapillary neoplasm (SPN) and pancreatoblastoma (PB). We distinguished their epidemiology, clinical and gross features, covered the newest reports about courses of treatment and systematised differential diagnoses. Although the most common pancreatic tumour, PDAC, has the highest malignant potential, it is still essential to properly classify and differentiate less-common lesions. It is vital to continue the search for new biomarkers, genetic mutations and the development of more specific biochemical tests for determining malignancy in rare pancreatic neoplasms.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rare Non-Neuroendocrine Pancreatic Tumours

Mormul

Włoszek

Nowoszewska

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…During the last 20 years, much research has been devoted to addressing this conundrum. The results have been remarkable, but at present, a major limitation with current treatment guidelines is the surgical overtreatment of IPMNs . Many surgical series have been published, and the findings have been condensed into guidelines .…”

Section: Introductionmentioning

confidence: 99%

“…The results have been remarkable, but at present, a major limitation with current treatment guidelines is the surgical overtreatment of IPMNs. 7,8 Many surgical series have been published, and the findings have been condensed into guidelines. [9][10][11] However, without considering the actual denominator at all (ie, those patients who are steered toward surveillance), the risk of developing malignant disease has always been overestimated.…”

mentioning

confidence: 99%

Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEThe progression of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas to malignant disease is still poorly understood. Observational and surgical series have failed to provide comprehensive information.OBJECTIVE To identify dynamic variables associated with the development of malignant neoplasms by combining pathological features with data from preoperative repeated observations. DESIGN, SETTING, AND PARTICIPANTSThe Crossover Observational Multicentric Study included a retrospective cohort of patients with branch-duct IPMNs (BD IPMNs) enrolled in a surveillance program from January 1, 2000, to December 31, 2019. Patients were enrolled from 5 referral centers: the Pancreas Institute, Verona,

show abstract

International Consensus Guidelines for the Management of Intraductal Papillary Mucinous Neoplasms

Goh

2022

The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases

View full text Add to dashboard Cite

Advances in the management of pancreatic cystic neoplasms

Cited by 8 publications

References 187 publications

Rare Non-Neuroendocrine Pancreatic Tumours

Rare Non-Neuroendocrine Pancreatic Tumours

Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery

International Consensus Guidelines for the Management of Intraductal Papillary Mucinous Neoplasms

Contact Info

Product

Resources

About